Thursday, 18 Oct 2018

RA/Inflammatory arthritis

Datesort ascending Type Title Save
09 Oct 2018 Social Be sure to remind your patients (Everyone) to get the flu vaccine - and if on MTX, hold MTX for 2 weeks. https://t.co/GOxazqE5aA
04 Oct 2018 News Predictive Risk Factors for Uveitis in JIA
04 Oct 2018 Social ILAR/PRINTO AGAIN !wants to again redefine JIA - as 4 groups: a) systemic JIA; b) RF+ JIA; c) enthesitis/SpA-related JIA; d) early-onset ANA+ JIA. Hopefully subsets will differ in MOA, outcomes, Treatments and NOT all be reported together in the future.https://t.co/qjEuvsC873
02 Oct 2018 News Elder Rheumatoids Less Likely to Receive Biologics
02 Oct 2018 Social 1223 patients with early RA in BARFOT studied over 8 yrs. Measures of hand & foot function improved in Year 1 but worsened thereafter. Finger flexion, pincer grip, & toe-standing most predictive & associated with Xray damage https://t.co/YvxslV2wUd
01 Oct 2018 News Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis
01 Oct 2018 News Defining Refractory Rheumatoid Arthritis
29 Sep 2018 Social Analysis of Veteran's Affairs RA data from 2006 to 2012, looked at escalating from MTX to MTX‐TNFi or triple therapy shows greater nonpersistence with triple Rx is related to AE from SSZ use. https://t.co/MBGMrnwKj0
27 Sep 2018 News Venous Thromboembolism Increased with Rheumatoid Arthritis, Not with TNF Inhibition
26 Sep 2018 News What Works in Undifferentiated Arthritis Patients
26 Sep 2018 Social Analysis of eteran's Affairs RA data from 2006 to 2012, looked at escalating from MTX to MTX‐TNFi or triple therapy shows nonpersistence with triple Rx is related to AE from SSZ use. https://t.co/MBGMrnwKj0
25 Sep 2018 Social Patients with preclinical RA (1st degree relative, serology+, arthralgia) should definitely change lifestyle before talking to their Rheumatologist about potential benefit/hazards of DMARD therapy. https://t.co/h4gpJgHHCw
25 Sep 2018 Social RT @sclerodermaUM: We received great feedback on our Self-Manage #Scleroderma newsletter. "Your email is ABSOLUTELY WONDERFUL! I hope this…
22 Sep 2018 Social Open study of adalimumab and infliximab in recalcitrant (RV) retinal vasculitis (unresponsive to other therapies) - 48 pts Rx (1/2 ADA, 1/2 INFL) - RV remission within 54% @3 mos and 86% @ 12 mos. with no added benefit to other cotherapies. https://t.co/EvbFj6vXly
20 Sep 2018 Social Chronic back pain suspected of having axial spondyloarthritis (axSpA) should not undergo follow-up MRI of the sacroiliac joint (MRI-SI) within a year if they had a previously negative baseline MRI-SI https://t.co/OoXDzcBTNd
20 Sep 2018 News Treat-to-Target in RA: No Increase in AEs
16 Sep 2018 Social FDA approves SC Actemra (tocilizumab) for systemic JIA (Stills disease) +/-MTX. IV TCZ was FDA approved In 2011 for SJIA. Approval is based on JIGSAW, a 52-wk study. sJIA dosing based on Weight ( <30 kg-162 mg q2wk; ≥30 162 mg qwk) https://t.co/kWXdwAh35Z
14 Sep 2018 Social Systemic onset JIA patients may have higher Injection Site Reaction rates when taking sc tocilizumab (45% sJIA) compared to polyarticular JIA (15-29%). RA ( 7-10%) or GCA https://t.co/ooDo1LjGlA
12 Sep 2018 Social RT @DrAiLynTan: In a difficult-to-treat #rheumatoid #arthritis survey ➡️50% chose DAS28>3.2 or presence of signs suggestive of active dise…
12 Sep 2018 News Mediterranean Diet Reduces Risk of Rheumatoid Arthritis